' /> ' /> ' />
A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Intensive Course in Cancer Risk Assessment Overview

Intensive Course in Cancer Risk Assessment Overview
To help address the growing demand for clinicians with interdisciplinary knowledge and skills in the practice of genetic cancer risk assessment (GCRA), the multifaceted Intensive Course in Cancer Risk Assessment and its Clinical Cancer Genetics Community of Practice (CCGCoP) leverage the expertise of the academic health center through Web-based tools to deliver accessible, evidence-based cancer genetics and genomics training, professional development, and practice-centered support at the point of care. The mission of the Intensive Course and CCGCoP is to increase the number of clinicians who are able to translate rapid advances in genetics and genomics into cancer risk assessment, management, and prevention practice. Realizing the promise of personalized medicine by promoting best practices in the delivery of GCRA services across the U.S. and internationally is the ultimate goal of the Clinical Cancer Genetics Community of Practice.
 
 
Objectives
 
At the conclusion of the course the participants should be able to:
  • Integrate cancer genetics and oncology knowledge into clinical practice
  • Apply skills commensurate with practitioner-level proficiency into the cancer risk assessment and case management process
  • Recommend risk-appropriate options for cancer surveillance and prevention as part of the cancer risk assessment, including imaging, chemo preventive and surgical interventions
  • Incorporate understanding of medical, legal, and psychosocial ramifications of cancer risk counseling and testing into clinical practice and research collaboration
  • Discuss clinical research methodologies in cancer genetics epidemiology and cancer prevention trials for high-risk cohorts
  • Recognize the roles and practical issues related to Human Subjects Protections, Informed Consent, Institutional Review Board and HIPAA in clinical research
  • Provide resources and information on current hereditary cancer registries, cancer epidemiology and cancer prevention studies to patients and professional colleagues
  • Use research training and support to participate in collaborative research activities
  • Realize greater professional self-efficacy related to cancer risk counseling and research participation skills
  • Incorporate web-based resources into ongoing practice-based education, professional development and research network support
 
 
Reaching Clinicians Around the Globe
 
City of Hope's Intensive Course in Cancer Risk Assessment has trained health care professionals in community settings across the United States as well as in Argentina, Brazil, Canada, Chile, Columbia, Germany, Hong Kong, Mexico, Peru, Philippines, Puerto Rico, Spain, Taiwan, Turkey, and Uruguay. Genetics on last line is misspelled. Participation of the Intensive Course alumni in the ongoing practice-centered professional development activities hosted by City of Hope has evolved into a dynamic international Clinical Cancer Genetics Community of Practice.
 
 

Accreditation

CME Credits
Accreditation Statement: Accreditation in process

Credit Designation: City of Hope designates this educational activity for a maximum of (TBD) AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The following may apply CME Category 1 credit for license renewal:

Registered Nurses: Nurses may report up to (TBD) credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). CME may be noted on the license renewal application in lieu of a BRN provider number.

Physician’s Assistants: The National Commission on Certification of Physician Assistants states that AMA accredited Category 1 courses are acceptable for CME requirements for recertification.

Genetic Counselor CEUs: The American Board of Genetic Counseling (ABGC) accepts CEUs approved by the National Society for Genetic Counselors (NSGC) for purposes of recertification. This event has been submitted to NSGC for approval of Category 1 CEUs and is approved for (TBD) CEUs and (TBD) Contact Hours.

Disclosure
The City of Hope adheres to ACCME Essential Areas, Standards for Commercial Support, and Policies regarding industry support of continuing medical education. Disclosure of the commercial relationships of everyone in a position to control content of an educational activity will be made at the activity. Speakers are also required to openly disclose discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.
 
No partial credit will be given. Participants should claim only those hours of credit that they actually spent at the educational activity.
 

Application Requirement

Click image to apply.
Application Deadline
 
Enrollment for the 2015 Winter course will begin on June 20, 2014. The deadline will be August 1, 2014.
 
Requirements
Please read all terms stated below before submitting application.

To receive full course credit, and certificate of course completion, course participants will be required to:
 
  • Participate in all distance and on-campus course related activities.
  • Complete all distance learning lecture modules delivered via Website and USB drive (flashdrive) interface by given deadlines.
  • Complete all pre- and post-course surveys, knowledge questionnaires, evaluations, and assignments as directed.
  • Agree to complete prescribed post-course professional development activities as outlined in the course syllabus. Some activities are required to be completed at 6-months post training and some must be completed by 1-year post training.
 
Selection Criteria
Preferred candidates are oncology or genetics-trained physicians, advanced practice nurses and genetic counselors currently providing or planning to initiate community-based clinical cancer genetics services.
 
 
How to Apply
 
Complete the Intensive Course Application and submit the following:
 
  • Completed application form
  • Letter from your institution indicating that protected time will be provided for course participation, and statement that you will have institutional support to provide cancer risk assessment upon return to your community (if applicable).
  • Current curriculum vitae (CV)
  • Mini-biography
  • Current headshot
 
Please NOTE: Applications will not be accepted without the items listed above.
 
Submit all of the above via regular mail, email or fax to:
 
Gloria Nuñez, Conference Coordinator
City of Hope
Division of Clinical Cancer Genetics, Mod 173
1500 East Duarte Road
Duarte, CA 91010-3000

Fax:
626-930-5495

Email:
gnunez@coh.org (note subject as "Intensive Course")
 
Acceptance
Applicants will be notified of acceptance by September 30, 2014, via e-mail. The non-refundable course fee (TBD) will be due on or before October 31, 2014.
 

Faculty

Course Co-directors
Jeffrey Weitzel, M.D.
Director, Division of Clinical Cancer Genetics
and
Kathleen R. Blazer, Ed.D., M.S., L.C.G.C.
Assistant Director, Cancer Genetics Education Program

City of Hope Faculty
Danielle Castillo, BS
Cathy Cole, RNC, NP, MPH
Josef Herzog, BS
Robert Morgan, Jr., MD, FACP
Bita Nehoray, MS, LCGC
Mariana Niell-Swiller, MS, CGC
Lacolle Robinson, BA
Sharon Sand, BA, CCRP
Ilana Solomon, ScM, MS, CGC
April Sorrell, MD
Sharon Wilczynski, MD, PhD

Guest Faculty
Kimberly Banks, MS, CGC, Ambry Genetics
Julie Culver, MS, LCGC, USC Norris Comprehensive Cancer Center
Allan Ebbin, MD, MPH, UnitedHealthcare (retired)
Carin Espenschied, MS, LCGC, Ambry Genetics
Carol Fabian, MD, University of Kansas Cancer Breast Cancer Prevention and Survivorship Centers
Lucille Leong, MD, City of Hope
Katrina Lowstuter, MS, CGC, USC Norris Comprehensive Cancer Center
Deborah J. MacDonald, PhD, RN, APNG, (former CCG faculty)
Hazel Mariveles, BS, (former CCG staff)
Susan Neuhausen, PhD, University of California Irvine
Gloria Petersen, PhD, Mayo Clinic
Charité Ricker, MS, CGC, LAC+USC Medical Center

Administrative Staff
Gloria Nuñez, Conference Coordinator
Stacy Berger, Programmer Analyst
Larry Kiang, Technology Specialist
Tracy Sulkin, Education Assistant

Intensive Course Alumni

City of Hope's Intensive Course in Cancer Risk Assessment has trained health professionals in community settings across the United States as well as in Argentina, Brazil, Canada, Chile, Columbia, Germany, Hong Kong, Mexico, Peru, Philippines, Puerto Rico, Spain, Taiwan, Turkey, and Uruguay.

Intensive Course Description

The Intensive Course and Clinical Cancer Genetics Community of Practice embody the tenets of practice-centered situated learning theory. Distance delivery of a modular curriculum responds to the practical time constraints of working clinicians and allows for flexible, self-directed study (e.g., oncologists can opt out of basic oncology content and focus more study time on genetics content, etc.). Concurrent participation in Working Group Clinical Cancer Genetics Web conferences reinforces didactic learning and Genetic Cancer Risk Assessment (GCRA) skills development. Participants have the option of participating in one of four training tracks to customize training to meet their learning needs.
 
 
Click the individual track link below for more information, including fees, and to download the track Calendar for 2015 Winter (calendar in progress).
 
 
All four tracks include distance didactic learning with corresponding Web conference reviews, and case-based training with Working Group Web conferences. Only Track 1 Full Spectrum Multi-modal Training includes four days of face-to-face program development workshops.
 
Upon completion of training, all participants receive support to apply new learning to practice through 12 months of self-directed engagement and activities as members of the Clinical Cancer Genetics Community of Practice.
 
 
 

Full Spectrum Distance-only Training

Click image to apply.
 
Phase 1:

(a) Attendance in a Web Conference Orientation session on Friday, November 14, 2014, (8:00-11:00 a.m. PT), and
 
(b) Complete 12 weeks of Distance Learning Modules with weekly Live Web-based discussion sessions every Friday morning (8:00-10:00 a.m. PT), and
 
(c) Participate in five (Live or Recorded) Working Group Case Conferences (Live Case Conferences are on Wednesdays, 10:00-11:30 a.m. PT), and
 
(d) Attend one Topics in Cancer Genetics Research (TOPICS) session (Fridays, 11:00 a.m.-12:00 noon)
 
Dates:  November 14, 2014 through February 20, 2015
 
Phase 2: (no on-campus workshops)
 

Phase 3:

Twelve months of self-directed continuing professional development and practice-centered support via Web Conference and Discussion Board activities. In addition, participants must present 1 case in Working Group and present once for TOPICS. 
 
 
Course requirements include:
 
  • Core Curriculum Modules:  3-4 assigned weekly
  • Pre-Post Case Scenarios
  • Pre-Post Course Knowledge Test
  • Weekly Friday review Web conferences
  • Five live or recorded Working Group case conferences
  • At least one Topics presentation
  • Pre-Post Surveys
  • Case Presentation (minimum of one risk assessment case from your practice)
  • Working Group Feedback Form (to accompany Working Group case conferencing)
  • 2 brief homework assignments (1 risk assessment, 1 Progeny pedigree drawing)
  • Prescribed Phase 3 Professional Development Activities (through 1 year post-course)
 
 
Fees:  (Payment is due on or before November 3, 2014)

MDs:  $1,600
RNs/GCs/Fellows/Pa-Cs:  $1,200
Industry:  $2,600
(Fees do not including travel or hotel)
 
Download the Track 2 calendar (under development)

Apply now: Intensive Course Application 2015 (The deadline to apply is August 1, 2014.)
 
 

Full Spectrum Multi-modal Training

Click image to apply.
 
Phase 1:

(a) Attendance in a Web Conference Orientation session on Friday, November 14, 2014, (8:00-11:00 a.m. PT), and
 
(b) Complete 12 weeks of Distance Learning Modules with weekly Live Web-based discussion sessions every Friday morning (8:00-10:00 a.m. PT), and
 
(c) Participate in five (Live or Recorded) Working Group Case Conferences (Live Case Conferences are on Wednesdays, 10:00-11:30 a.m. PT), and
 
(d) Attend one Topics in Cancer Genetics Research (TOPICS) session (Fridays, 11:00 a.m.-12:00 noon)
 
Dates:  November 14, 2014 through February 20, 2015
 
Phase 2:

Four days of face-to-face Cancer Genetics Workshops on-campus at City of Hope in Duarte, CA.
 
Dates:  February 23 - 26, 2015
 
Phase 3:

Twelve months of self-directed continuing professional development and practice-centered support via Web Conference and Discussion Board activities. In addition, participants must present 1 case in Working Group and present once for TOPICS. 
 
 
Course requirements include:
 
  • Core Curriculum Modules:  3-4 assigned weekly
  • Pre-Post Case Scenarios
  • Pre-Post Course Knowledge Test
  • Weekly Friday review Web conferences
  • Five live or recorded Working Group case conferences
  • At least one Topics presentation
  • Pre-Post Surveys
  • Case Presentation (minimum of one risk assessment case from your practice)
  • Working Group Feedback Form (to accompany Working Group case conferencing)
  • 2 brief homework assignments (1 risk assessment, 1 Progeny pedigree drawing)
  • Prescribed Phase 3 Professional Development Activities (through 1 year post-course)
 
 
Fees:  (Payment is due on or before November 3, 2014)

MDs:  $2,000
RNs/GCs/Fellows/Pa-Cs:  $1,600
Industry:  $3,000
(Fees do not including travel or hotel)
 
Download the Track 1 calendar (under development)

Apply now:  Intensive Course Application 2015 (The deadline to apply is August 1, 2014.)
 
 

Breast-Ovarian OR G.I. Sub-specialty Training

Click image to apply.
 
Phase 1:

(a) Attendance in a Web Conference Orientation session on Friday, November 14, 2014, (8:00-11:00 a.m. PT), and
 
(b) Complete Distance Learning Modules (subset of full curriculum delivered over 12 weeks with Live Web-based discussion sessions Friday mornings (8:00-10:00 a.m. PT), and
 
(c) Participate in five (Live or Recorded) Working Group Case Conferences (Live Case Conferences are on Wednesdays, 10:00-11:30 a.m. PT), and
 
(d) Attend one Topics in Cancer Genetics Research (TOPICS) session (Fridays, 11:00 a.m.-12:00 noon)
 
Dates:  November 14, 2014 through February 20, 2015
 
Phase 2: (no on-campus workshops)
 
Phase 3:

Twelve months of self-directed continuing professional development and practice-centered support via Web Conference and Discussion Board activities. In addition, participants must present 1 case in Working Group and present once for TOPICS. 
 
 
Course requirements include:
 
  • Core Curriculum Modules:  3-4 assigned weekly
  • Pre-Post Case Scenarios
  • Pre-Post Course Knowledge Test
  • Weekly Friday review Web conferences
  • Five live or recorded Working Group case conferences
  • At least one Topics presentation
  • Pre-Post Surveys
  • Case Presentation (minimum of one risk assessment case from your practice)
  • Working Group Feedback Form (to accompany Working Group case conferencing)
  • 2 brief homework assignments (1 risk assessment, 1 Progeny pedigree drawing)
  • Prescribed Phase 3 Professional Development Activities (through 1 year post-course)
 
 
Fees:  (Payment is due on or before November 3, 2014)

MDs:  $1,600
RNs/GCs/Fellows/Pa-Cs:  $1,200
Industry:  $2,600
(Fees do not including travel or hotel)
 
Download the Track 3 and 4 calendar (under development)

Apply now:  Intensive Course Application 2015 (The deadline to apply is August 1, 2014.)
 
 
 
 

CCG Community of Practice

City of Hope Clinical Cancer Genetics Community of Practice brings cancer genetics practitioners from diverse practice settings together for professional learning, enduring patient-centered support and dynamic community-based research collaborations to promote quality care and improved patient outcomes across the U.S. and internationally.
 
Working Group
 
Clinical Cancer Genetics (CCG) Working Group is a CME-accredited interdisciplinary cancer genetics case conference series conducted each week by the City of Hope clinical team.
 
TICGR Topics in Cancer Genetics Research
 
Topics in Clinical Cancer Genetics (TICGR) is a weekly one-hour CME-accredited web-conference seminar series focused on timely issues in clinical cancer genetics, cancer epidemiology and cancer genetics research, alternating between didactic lectures, case-based literature reviews and basic research journal club.
 

A Web-based discussion board for collaborative, interdisciplinary practice-based support and continuing professional learning.
 
Knowledge Center
 
Knowledge Center Information coming soon
 

A large research group of over 40 collaborating sites in the 40 collaborating sites in the United States, Mexico, and South America. As members of the CCGCRN, research collaborators can use the message board and forums to post questions and communicate with other members in the network.
 
Clinical Cancer Genetics
The City of Hope Division of Clinical Cancer Genetics is committed to being a national leader in the advancement of cancer genetics, screening and prevention, through innovative patient care, research and education.

Contact Us
  • 800-826-HOPE (4673)
  • For more information about the Cancer Screening & Prevention Program, call 626-256-8662, ext. 2.
CCG Newsletter: Closing the Loop
View the current issue: CCG Newsletter
Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
NEWS & UPDATES
  • Learn more about becoming a patient or getting a second opinion at City of Hope by visiting us online or by calling 800-826-HOPE (4673). City of Hope staff will explain what’s required for a consult at City of Hope and help you determine, before you come in, whether or not your insurance will pay for the ...
  • Counter-intuitive though it might seem, a prostate cancer diagnosis shouldn’t always lead to immediate prostate cancer treatment. Although prostate cancer is the second-leading cancer killer of men, behind lung cancer, and causes more than 29,000 deaths in the U.S. each year, in many cases, the tumors are...
  • Radiology is one of the cornerstones of any hospital. It is a key diagnostic branch of medicine essential for the initial diagnosis of many diseases and has an important role in monitoring a patient’s treatment and predicting outcome. Radiology is the specialty considered to be both the “eyes” and “ears” of med...
  • Donating blood and platelets saves lives. We all know this. Yet every summer, potential blood donors become distracted by vacations and schedule changes. As a result, blood donations fall dramatically across the nation, leaving hospitals frantically trying to bring in much-needed blood for their patients. Earli...
  • To be a great cancer hospital, you need a great oncology program. Just ask City of Hope – and Becker’s Hospital Review. The health care publishing industry stalwart, described as the “leading hospital magazine for hospital business news and analysis for hospital and health system executives,” recently selected ...
  • Diagnostic errors are far from uncommon. In fact, a recent study found that they affect about 12 million people, or 1 in 20 patients,  in the U.S. each year. With cancer, those errors in diagnosis can have a profound impact. A missed or delayed diagnosis can make the disease that much harder to treat, as the Ag...
  • Eleven years ago, lymphoma patient Christine Pechera began the long road toward a cancer-free life. She had been diagnosed with non-Hodgkin lymphoma and told by doctors elsewhere that her lifespan likely would be measured in months, not years. Refusing to give up, she came to City of Hope for a second opinion. ...
  • Brain surgery is not for the faint of heart. It takes courage, as well as curiosity and compassion. The truly great surgeons also have a desire to find new, and better ways, of healing the brain. Enter Behnam Badie, M.D., chief of neurosurgery at City of Hope. Now a pioneer in brain tumor treatment, Badie enter...
  • Elizabeth Budde, M.D., Ph.D., wants to encourage infighting. She aims to turn the immune system on itself — to the benefit of patients with acute myeloid leukemia, or AML. AML arises when abnormal white blood cells grow out of control, amassing in the bone marrow and interfering with normal blood cell developme...
  • Six, to date; more soon. Outpatient bone marrow transplants, that is. Finding new ways to deliver quality care with the greatest benefit is a priority for a patient-centered institution like City of Hope. For example, not every bone marrow transplant patient needs to check into the hospital for treatment. In fa...
  • The best measure of success in the fight against cancer is in lives saved and families intact, in extra days made special simply because they exist. Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, understands what precedes that special awareness. When cancer strikes, one minute a person ma...
  • In cancer, expertise matters. So do survival rates, patient safety, patient services and many other factors. City of Hope understands this, as does U.S.News & World Report. The magazine’s 2014-2015 list of best hospitals for cancer once again includes City of Hope, ranking the institution 12 out of 900 elig...
  • At 29, Kommah McDowell was a successful young professional engaged to be married to her best friend. She worked in the financial services sector and kick-boxed to keep in shape and to relax. Then came the diagnosis of triple-negative inflammatory breast cancer, a rare and very aggressive form of breast cancer. ...
  • The well-known drug tamoxifen might not always be the best choice for premenopausal women who have undergone treatment for breast cancer and face a heightened risk of recurrence. A new study suggests that the aromatase inhibitor exemestane, or Aromasin, works slightly better than tamoxifen in preventing cancer ...
  • At age 44, Bridget Hanchette, a mother of three from La Crosse, Wisconsin, was diagnosed with grade IV glioblastoma, the most aggressive type of malignant brain tumor. The cancer grows and spreads quickly, making it difficult to treat. Most patients with this diagnosis are not given much hope, but Hanchette’s i...